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AbstrACt
Objectives Hodgkin’s lymphoma (HL) is the the most 
common cancer in teenagers and young adults. This 
nationwide study conducted over a 25-year period in the 
UK investigates variation in HL incidence by age, sex, 
region and deprivation to identify trends and high-risk 
populations for HL development.
Design Population-based cohort study.
setting Clinical Practice Research Datalink (CPRD) 
electronic primary care records linked to Hospital Episode 
Statistics and Index of Multiple Deprivation data were 
used.
Participants Data on 10 million individuals in the UK from 
1992 to 2016 were analysed.
Primary and secondary outcome measures Poisson 
models were used to explore differences in HL incidence 
by age, sex, region and deprivation. Age-specific HL 
incidence rates by sex and directly age-standardised 
incidence rates by region and deprivation group were 
calculated.
results A total of 2402 new cases of HL were identified 
over 78 569 436 person-years. There was significant 
variation in HL incidence by deprivation group. Individuals 
living in the most affluent areas had HL incidence 60% 
higher than those living in the most deprived (incidence 
rate ratios (IRR) 1.60, 95% CI 1.40 to 1.83), with strong 
evidence of a marked linear trend towards increasing HL 
incidence with decreasing deprivation (p=<0.001). There 
was significant regional variation in HL incidence across 
the UK, which persisted after adjusting for age, sex and 
deprivation (IRR 0.80–1.42, p=<0.001).
Conclusions This study identified high-risk regions 
for HL development in the UK and observed a trend 
towards higher incidence of HL in individuals living in 
less deprived areas. Consistent with findings from other 
immune-mediated diseases, this study supports the 
hypothesis that an affluent childhood environment may 
predispose to development of immune-related neoplasms, 
potentially through fewer immune challenges interfering 
with immune maturation in early life. Understanding 
the mechanisms behind this immune dysfunction could 
inform prevention, detection and treatment of HL and 
other immune diseases.
IntrODuCtIOn
Hodgkin’s lymphoma (HL) is the the most 
common cancer in teenagers and young 
adults worldwide.1 2 In the UK, 2100 new 
cases of HL are diagnosed each year, but 
little is known about the distribution of these 
cases in the UK population or if there are any 
high-risk groups. International studies have 
identified that HL incidence varies consid-
erably between countries, with higher rates 
observed in high-income countries.3–7 This 
pattern is also seen within countries, with 
the US studies showing higher rates in more 
affluent regions and geographical variation in 
HL incidence between different states.8 Few 
UK studies have investigated HL incidence 
patterns by socioeconomic deprivation9–12 
and region12–14 and the results have been 
conflicting and inconclusive. In addition, to 
our knowledge there have been no recent 
strengths and limitations of this study
 ► Our population-based data covered a large repre-
sentative sample of over 10 million individuals in 
the UK over a 25-year period with 78 million years 
of follow-up.
 ► We used UK primary care electronic health records 
linked to secondary care data and Index of Multiple 
Deprivation data to improve capture of Hodgkin’s 
lymphoma diagnoses and allow analysis of geo-
graphical and deprivation-based trends.
 ► Data from the Clinical Practice Research Datalink 
(CPRD) used in this study have been demonstrated 
to be generalisable to the UK population across a 
number of demographics.
 ► Data in this study were not linked to the National 
Cancer Register (NCR), which is a potential limita-
tion; however lymphoma diagnosis in CPRD has 
been validated in previous studies and shown to 
have high concordance with the NCR.
 ► This is a cohort study of a representative sample of 
the UK population and not the whole UK population.
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studies investigating patterns of HL incidence in the UK 
population since 2010. Understanding how HL incidence 
varies between different geographical regions in the UK 
and identifying high-risk populations may provide clues 
to the underlying aetiology of the disease and inform 
future research directions. We aimed to conduct a popu-
lation-based cohort study of 10 million individuals over a 
25-year period using linked primary and secondary care 
electronic health records to investigate variation in HL 
incidence within the UK by age, sex, geographic region 
and deprivation.
MAterIAls AnD MethODs
Data sources and study population
Data were obtained from the UK Clinical Practice 
Research Datalink (CPRD), linked to Hospital Episode 
Statistic (HES) inpatient data and Index of Multiple 
Deprivation (IMD) data. CPRD is an electronic health 
record database containing prospectively collected pseu-
do-anonymised data from UK primary care consultations. 
It is the largest source of longitudinal primary care data, 
holding information on 22 million patients representing 
approximately 9% of the UK population (in 2013).15 This 
database has been shown to be largely representative of 
the UK population across a number of demographics 
including age, sex and ethnicity.15 Data are available 
from 1987 onwards when CPRD was first established. 
Practices contributing to CPRD are regularly audited 
to ensure high-data quality and that 95% of prescribing 
and morbidity events are captured before practices are 
declared ‘up-to-standard’ (UTS) for research purposes.16 
HES data provide additional information from hospital 
attendances in England. IMD scores represent a 
composite ecological (small-area based) measure of the 
socioeconomic status of a patient, based on the income, 
employment, disability, educational attainment and other 
attributes of the Local Super Output Area (LSOA) of a 
patient’s residence. The latter typically comprise popu-
lations between 1000 and 3000 residents. All patients 
had an aggregate IMD score pertaining to the LSOA of 
their own residence (0.1% of population) or that of their 
general practice (99.9%) taken from the earliest available 
linked IMD dataset (2004 for patient-level and 2009 for 
practice-level).
The study population comprised patients actively regis-
tered with a CPRD practice between January 1992 and 
December 2016 who did not have a pre-existing diag-
nosis of HL. In accordance with previous studies, eligible 
follow-up time in days for each patient was commenced 
from 1 year after the patient registered with the practice 
(to avoid capturing past diagnoses recorded retrospec-
tively in the few months after new patient registration),17 
or from when CPRD classified the General Practice (GP) 
surgery to be UTS if this occurred later. Active follow-up 
ended when a patient received a diagnosis of HL, died, 
left a CPRD practice or at the last data collection date for 
participating practices, whichever occurred earlier.
Classification of outcome and exposure
Data were obtained on HL diagnoses coded using Read 
codes (in CPRD) or the International Classifications of 
Diseases, 10th Revision codes (in HES) (online supple-
mentary tables S1 and S2); age and date of diagnosis; area 
of residence by Strategic Health Authority region; depri-
vation using IMD quintiles; date of birth and sex.
statistical analysis
For each new case of HL, the year and age at diagnosis 
were determined and the patient was counted as an inci-
dent case for that calendar year and age group. The dura-
tion of active follow-up in CPRD for each individual in the 
study population was then calculated and used to calcu-
late the total person-years at risk (PYAR) and to estimate 
crude HL incidence rates per 100 000 PYAR.
Age-specific HL incidence rates were calculated in 
5-year age bands, first for persons and then stratified 
by sex. Age-standardised incidence rates were estimated 
by the direct method using the European standard 
population for each region and deprivation quintile. 
Poisson regression was used to model HL incidence rate 
ratios (IRRs) for region, deprivation, age and sex inde-
pendently before adjusting for other variables. East of 
England was used as the reference category for region, as 
the region with the age-standardised incidence estimate 
that was closest to the national average.18 Deprivation was 
initially included as a categorical variable in the regres-
sion analysis to calculate IRRs and then subsequently we 
assessed for a linear trend by deprivation quintile, first 
by estimating the linear effect of deprivation using like-
lihood ratio tests, and then investigating departure from 
linearity by comparing models in which deprivation was 
added as a non-linear vs a linear term. In addition, inci-
dence rates by deprivation were examined to see if any 
variation persisted after adjusting for trends in region, 
and vice versa to see if trends in region were observed 
after adjusting for deprivation as a categorical variable. 
Adjusted models were also adjusted for age and sex.
HL has a bimodal age-specific incidence pattern with 
the first peak occurring between 15 and 34 years and a 
second peak between 70 and 84 years.18 Previous studies 
have suggested HL in individuals aged <50 and>50 is 
likely to have different aetiological factors. We therefore 
performed pre-specified subgroup analyses by sex (male 
vs female) and age (≤50 vs>50 years). We additionally 
examined interactions between exposure variables in the 
final model, particularly given potential variation in risk 
of HL by age and sex18 that is, age group by sex, age group 
by deprivation, age group by region, sex by deprivation 
and sex by region. Deprivation group was treated as a 
categorical variable in interaction terms. Analyses were 
performed using Stata V.15.
Patient and public involvement
The development of the research question for this 
study and aspects of the study design, particularly the 
subgroup analysis of the outcome by sex and age group, 
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Figure 1 Age-specific Hodgkin’s lymphoma incidence in the study population (cohort of the UK population): overall (left panel) 
and by sex (right panel), with 95% CI bars.
were informed by discussions with HL patients’ and their 
friends and relatives. The research focus of this study 
reflects their experiences and expressed research prior-
ities in this field. Results will be shared with patient and 
public advisers and publicised on the CPRD website with 
details of the open-access paper.
results
There were 2402 new diagnoses of HL identified over 
the 25-year study period (78 569 436 person-years of 
follow-up) with an overall HL incidence of 3.06 cases per 
100 000 PYAR (95% CI 2.94 to 3.18). About 47.2% of cases 
were identified using CPRD alone, 16.9% were identified 
using HES alone and 35.9% were identified in both data-
sets. Age-specific HL incidence showed a bimodal distri-
bution with an initial peak at ages 20–24 years followed 
by a second peak at ages 70–74 years characteristic of 
HL incidence in high-income countries (figure 1, online 
supplementary tables S3 and S4). Incidence was higher 
in older adults compared with those aged ≤50 (4.12 cases 
per 100 000 PYAR, 95% CI 3.89 to 4.36 vs 2.46 cases per 
100 000 PYAR, 95% CI 2.32 to 2.59) and was higher in men 
than in women in all age groups (with an overall IRR for 
males vs females of 1.26, 95% CI 1.16 to 1.36 and age-spe-
cific IRRs ranging from 1.16 to 1.82) except for 15–29 
years when incidence in female individuals exceeded that 
of male individuals (age-specific IRRs 0.82–0.90) and at 
the extremes of the age range where the number of cases 
were small (figure 1, online supplementary table S3). Of 
the 2402 incident cases of HL, 52.8% were identified in 
HES (407 not in CPRD), 83.1% in CPRD (1133 not in 
HES) and 35.9% were identified in both.
regional variation
Age-standardised incidence rates showed variation in HL 
incidence across the UK with the North East of England 
having the highest rates (3.89 cases per 100 000 PYAR) and 
Scotland having the lowest (2.35 cases per 100 000 PYAR) 
(figure 2, online supplementary table S4). Multivariable 
Poisson regression revealed strong evidence for an asso-
ciation between geographical region and HL incidence 
(table 1), which persisted after adjusting for deprivation, 
age and sex (p=<0.001). Subgroup analysis showed that 
regional variation in HL incidence was observed in both 
men and women, but was limited to individuals aged over 
50 years, without evidence for an association between 
region and HL incidence demonstrated in the younger 
age group (p=0.23).
socioeconomic deprivation
There was strong evidence for an association between 
HL incidence and deprivation (p≤0.001), with age-stan-
dardised incidence being highest in the most affluent 
population groups and lowest in the most deprived (3.92 
cases per 100 000 PYAR vs 2.55 cases per 100 000 PYAR 
(online supplementary table S4)). Poisson regression 
showed that the least deprived group had HL incidence 
rates over 60% higher than the most deprived one, after 
adjusting for other factors (IRR=1.60, 95%CI 1.40 to 1.83, 
table 1). The strong evidence of a marked linear trend 
towards lower rates of HL incidence with increasing 
deprivation persisted after adjusting for region and was 
observed across both sexes and when analysing young 
and old adults separately (figure 3, table 1).
Interaction analysis
Further exploring the subgroup analysis outlined above, 
there was no evidence that regional differences in HL 
incidence varied by age or sex (Pinteraction=0.40 and 1.00, 
respectively). In addition, there was no evidence that 
the association between deprivation and HL risk varied 
by age or sex (Pinteraction=0.57 and 0.39, respectively). The 
characteristic bimodal age-specific HL incidence pattern 
was observed in both men and women, and the associa-
tion between age and HL incidence did not vary by sex 
(Pinteraction=0.16).
DIsCussIOn
This is the largest study to date investigating variability in 
HL incidence by age, sex, deprivation and sub-national 
geography. It uses linked electronic primary care records 
over a 25-year period in a representative cohort of the 
UK population. We found strong evidence that lower 
levels of deprivation are associated with higher incidence 
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Figure 2 Age-standardised Hodgkin’s lymphoma incidence in the study population (cohort of the UK population) by region. 
PYAR, person-years at risk.
of HL, an association observed across age groups. There 
was considerable variation in HL incidence by the UK 
geographical region, and these differences persisted after 
sex, age and deprivation were taken into account.
Comparison with the literature
The bimodal age-specific HL incidence pattern described 
in this study is consistent with findings from other 
high-income countries, including previous studies in 
the UK.3 5–7 18–22 Higher incidence of HL in men except 
between ages 15 and 29 has also been observed in 
previous UK studies, which found higher incidence in 
women aged 15–24.18 21 When looking at the association 
with deprivation previous studies have shown heteroge-
neous outcomes. A previous UK study found that HL inci-
dence in men between 2006 and 2010 was greater in more 
deprived areas, without finding associations between 
deprivation and HL in the earlier study era (1996–2006) 
in either sex.9 Another study investigating the distribution 
of childhood cancers in the UK between 1969 and 1993 
found HL incidence in children aged 0–9 was greater in 
more deprived areas.11 In contrast, two previous studies 
conducted in parts of England and Wales reported 
higher HL incidence with higher socioeconomic status 
in individuals aged 0–24,10 12 concordant with our study 
findings, which are based on a population of 10 million 
people followed-up over a longer time period, broader 
geographic area and including patients other than young 
adults, adolescents and children. The observation of 
inverse socioeconomic gradients for incidence of HL in 
older adults in our study is a finding which to our knowl-
edge has not been previously reported. With regards to 
regional variation, the previous literature has also been 
conflicting. Quinn et al and McKinney et al reported no 
clear geographical variation in HL incidence rates within 
the UK population.13 14 Alston et al however reported 
strong evidence that HL incidence varied by UK region, 
with greater incidence in London and the South East of 
England among individuals aged 0–24 years.12 These find-
ings concord with those of our study, which demonstrated 
significant regional variation in HL incidence across the 
UK with greater incidence in London and the South 
East. Regional variations were present in both men and 
women, but were limited to older adults, although this 
may reflect power limitations rather than a true lack of an 
effect in younger adults.
strengths and limitations
The main strengths of our study are that it is a large popu-
lation-based study of more than 10 million individuals and 
has a long follow-up. HL is a relatively rare disease and the 
sample size and follow-up length allow for smaller effect 
sizes and interactions that could be missed in smaller 
studies to be detected. This is particularly important 
due to the growing evidence for two potentially separate 
aetiological pathways underlying HL incidence in young 
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Table 1 Hodgkin’s lymphoma risk by sex, socioeconomic status and geographical region
Adjusted IRR (95% CI)*
 Risk factors Study population ≤50 Years >50 Years Male population
Female 
population
Sex
  Male 1.30 (1.20 to 1.41) 1.23 (1.10 to 1.38) 1.38 (1.23 to 1.55)
  P value <0.001 <0.001 <0.001
Region
  East of England ref ref ref ref ref
  North East England 1.42 (1.05 to 1.93) 0.82 (0.48 to 1.40) 2.05 (1.40 to 3.01) 1.49 (1.00 to 2.24) 1.34 (0.84 to 2.13)
  Yorkshire/Humber 1.32 (1.04 to 1.68) 1.11 (0.78 to 1.58) 1.55 (1.12 to 2.13) 1.48 (1.08 to 2.01) 1.15 (0.79 to 1.66)
  London 1.29 (1.08 to 1.54) 1.15 (0.90 to 1.48) 1.45 (1.13 to 1.87) 1.25 (0.99 to 1.59) 1.33 (1.02 to 1.73)
  South East Coast 1.23 (1.03 to 1.48) 1.24 (0.96 to 1.59) 1.24 (0.97 to 1.59) 1.19 (0.94 to 1.51) 1.29 (0.99 to 1.69)
  North West England 1.07 (0.89 to 1.28) 1.05 (0.82 to 1.36) 1.07 (0.83 to 1.39) 1.13 (0.89 to 1.43) 0.99 (0.75 to 1.31)
  South West England 1.06 (0.87 to 1.29) 1.08 (0.82 to 1.43) 1.04 (0.78 to 1.37) 1.05 0.81 to 1.36) 1.07 (0.80 to 1.43)
  West Midlands 1.00 (0.82 to 1.21) 0.90 (0.68 to 1.20) 1.10 (0.83 to 1.44) 0.96 (0.74 to 1.26) 1.04 (0.78 to 1.40)
  Wales 0.97 (0.80 to 1.18) 1.08 (0.83 to 1.42) 0.87 (0.65 to 1.15) 0.96 (0.74 to 1.25) 0.98 (0.73 to 1.32)
  South Central 
England
0.96 (0.80 to 1.15) 0.96 (0.75 to 1.24) 0.95 (0.73 to 1.23) 0.87 (0.68 to 1.11) 1.08 (0.82 to 1.42)
  East Midlands 0.95 (0.73 to 1.23) 1.10 (0.78 to 1.54) 0.79 (0.53 to 1.17) 0.94 (0.67 to 1.34) 0.96 (0.65 to 1.42)
  Northern Ireland 0.90 (0.68 to 1.17) 0.78 (0.53 to 1.15) 1.02 (0.70 to 1.48) 0.90 (0.63 to 1.29) 0.90 (0.60 to 1.06)
  Scotland 0.80 (0.66 to 0.98) 0.89 (0.68 to 1.17) 0.71 (0.53 to 0.96) 0.82 (0.63 to 1.08) 0.78 (0.57 to 1.06)
  P value <0.001 0.23 <0.001 0.002 0.03
IMD quintile
  5 (most deprived) ref ref ref ref ref
  4 1.10 (0.96 to 1.26) 1.20 (1.00 to 1.45) 1.01 (0.83 to 1.23) 1.11 (0.92 to 1.34) 1.09 (0.89 to 1.33)
  3 1.15 (1.00 to 1.32) 1.12 (0.92 to 1.36) 1.18 (0.97 to 1.44) 1.21 (1.00 to 1.47) 1.08 (0.88 to 1.33)
  2 1.35 (1.18 to 1.55) 1.37 (1.13 to 1.66) 1.33 (1.10 to 1.62) 1.45 (1.21 to 1.75) 1.25 (1.02 to 1.52)
  1 (least deprived) 1.60 (1.40 to 1.83) 1.55 (1.29 to 1.88) 1.63 (1.35 to 1.97) 1.87 (1.57 to 2.24) 1.31 (1.07 to 1.61)
  P value <0.001† <0.001† <0.001† <0.001† 0.003†
*Adjusted IRR, Incidence rate ratio adjusted for age, sex, region and IMD quintile.
†P value from test for linear trend.
IMD, Index of Multiple Deprivation; p, p value from likelihood-ratio test; ref, reference group (East of England used as the reference category 
as the region with age-standardised incidence estimate that was closest to the national average).
Figure 3 Age-standardised Hodgkin’s lymphoma incidence in the study population (cohort of the UK population) by 
deprivation: in men and women (left panel) and in individuals aged ≤50 compared with >50 (right panel). PYAR, person-years at 
risk.
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and older adults, and therefore the need for them to 
be analysed independently.3 4 23 A further advantage of 
this study was the use of CPRD data with regional infor-
mation, linked to HES and deprivation data. CPRD has 
wide national coverage and has been demonstrated to be 
representative of the UK population across a number of 
demographics making the results generalisable to the UK 
population.15
The main limitation of this study is the that it did not 
have access to linked data from the UK National Cancer 
Registry (NCR), which can be considered to represent 
the gold standard for estimating HL incidence. This 
could result in potential misclassification of cases and 
controls in this study and subsequent underestimation 
of effect estimates. Previous concordance studies have 
demonstrated that HL diagnoses have high validity in 
CPRD when compared with the NCR (positive predic-
tive value for lymphoma 89.6%, sensitivity 97.3%) and 
any such effect is therefore unlikely to have materially 
affected the findings.24 In addition, CPRD has estab-
lished use in cancer epidemiology in the literature24–27 
and previous population-based cohort studies have 
demonstrated the feasibility of HL research using 
CPRD.28–30 Outcome misclassification in this study was 
further reduced through use of HES-linked data, which 
improved validity of HL diagnoses by supplementing GP 
records with hospital data to capture cases that might 
have been missed in CPRD. Data was also not available 
on HL subtype and EBV positivity status, which would 
be informative for subgroup analysis to assess if trends in 
deprivation varied by histological group. This could be 
explored in future studies. Another limitation is the use 
of routinely collected data with potential misclassification 
of an individual’s deprivation group. Deprivation was 
determined using IMD which is based on the postcode of 
the patients residence or registered GP practice and not 
on individual-level characteristics. As there may be varia-
tion in deprivation within a postcode, especially in highly 
diverse inner-city areas, this could result in non-differen-
tial misclassification of deprivation and underestimation 
of any effects. Additionally, the deprivation quintile and 
region captured from the dataset and used in the study 
may not represent childhood deprivation groups and 
region of residence, which may be more appropriate if 
early-life exposures are involved in the aetiology of HL. 
The earliest available linked IMD scores (2004 for patient 
level and 2009 for practice-level) were used in this study 
to estimate deprivation. This assumes both that an indi-
viduals IMD status remains stable throughout their life, 
and that the IMD quintile of a postcode remains stable 
over time. Both of these assumptions may not be true as 
individuals can move between deprivation quintiles and 
areas may undergo gentrification over time. Population 
movement also means an individuals childhood resi-
dence may differ from their current regional residence, 
which could dilute any regional variation observed in HL 
incidence.
Implications
The bimodal incidence pattern and differences in 
regional variation between younger versus older adults 
supports the hypothesis that there may be different aeti-
ological pathways involved in the development of HL 
in these age groups.3 4 19 This is further supported by 
evidence from previous studies for different distributions 
of the histological subtypes of HL between the two age 
groups.5 7 8 23 31–33 Consideration should be given to inves-
tigating HL aetiology separately in these age groups in 
future studies to identify potential different contributory 
factors that could be masked when analysing the popula-
tion as a whole. In addition, the existence of potentially 
different pathophysiology could have important implica-
tions for targeting and response to treatment regimens 
and in disease monitoring and detection. The peak in 
disease incidence in young female adults is characteristic 
of a number of immune-related conditions, including 
multiple sclerosis, rheumatoid arthritis and lupus.34–36 
Similarities between incidence patterns for these diseases 
could suggest a common predisposing factor in early life 
that interferes with immune regulation and promotes 
development of immune-related diseases in young adults.
The trend towards increased HL incidence with 
increased affluence was replicated across three separate 
UK databases and is consistent with findings from the US 
studies.8 10 12 Concordance between these findings add 
further support for this being a true association. This 
trend has been previously well established in ecological 
studies making comparisons between countries with very 
different levels of deprivation.3–7 Within country differ-
ences in deprivation tend to be much smaller than those 
seen between countries. Our results could suggest that 
even small increases in community deprivation levels may 
elevate an individual’s risk of developing HL. A proposed 
explanation for this association is that children in affluent 
households with less overcrowding and cleaner childhood 
environments consequently have delayed exposure to 
infectious agents and fewer immune challenges in early-
life to stimulate immune development and regulation.37–42 
This predisposes them to develop immune-related condi-
tions. This phenomenon has been demonstrated for 
other haematological malignancies, including leukaemia, 
where low-infection burden and lack of microbial expo-
sure in early life were found to result in immune system 
malfunction and were associated with increased risk of 
developing subsequent leukaemia.43 Observation of this 
trend in older adults is less likely to be explained by child-
hood exposures. HL aetiology could be multifactorial 
with childhood exposures predisposing individuals, but 
in the absence of other promoting factors in early-life, 
onset of HL is delayed until later adulthood. This should 
be further explored in future studies to identify contrib-
utory factors underlying the association in older adults.
Regional variation in HL incidence was observed after 
adjusting for deprivation differences in older adults. This 
indicates that other factors that vary geographically in 
these regions are contributing to increased HL incidence 
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in this age group. Geographical clustering of HL cases 
has been previously reported in both the UK and the 
USA,8 12 44–47 which could support the role for an environ-
mental factor underlying increased rates in these regions. 
Other possible contributory factors include regional 
differences in ethnicity and clustering of predisposing 
or protective genotypes. Further studies are required to 
investigate the role of these different factors in regional 
variation in UK HL incidence.
COnClusIOn
This study of over 10 million individuals based on nation-
wide primary care data found strong evidence for regional 
variation in HL incidence across the UK that cannot be 
explained by geographical differences in deprivation. 
More affluent individuals within the UK population have a 
significantly higher risk of developing HL in both younger 
and older adults. This trend has been observed for other 
immune-mediated diseases. The findings are consistent 
with the hypothesis that an affluent childhood environ-
ment may predispose to development of immune-related 
conditions, possibly through fewer immune challenges 
interfering with the maturation of the immune system. 
Further understanding the responsible pathophysiolog-
ical mechanisms could inform prevention, detection and 
treatment of HL and other immune conditions.
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